This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The goal of the Mayo Clinic CTSA application is to present our vision for the integration and expansion of our innovative clinical and translational research activities, so that a highly functional academic home for clinical and translational research is developed at the Mayo Clinic. This new Center for Clinical and Translational Research (CCTR) will be founded on Mayo's long-standing excellence in and commitment to clinical and translational research, which includes the support of key infrastructure and a commitment to career development. To achieve this goal we describe a comprehensive approach to the key elements of the CTSA RFA and focus on enhancing: 1) Clinical Research Core Resources that provide innovative tools to investigators;2) Career Development and Education Programs that prepare the next generation of investigators;3) Compliance and Regulatory Affairs Support that ensures patient safety and privacy, and customer service-oriented approaches to support investigative teams;4) Community Affairs support to enhance participation, diversity and community support for clinical and translational research;5) Collaboration with Industry and Clinical Practices to translate research discoveries into routine clinical practice;and 6) Continued and Expanded Institutional Support that includes an """"""""academic home"""""""" for clinical and translational research. We also propose a consolidated governance plan that incorporates strong data-driven evaluation of each CCTR element and the program as a whole. In principle, the CTSA program is consistent with the historical, conceptual and philosophical underpinnings of Mayo Clinic, and in this application we clearly articulate our vision of how the overarching and transformative goals of the CTSA program can be met at Mayo. Additionally, we have the """"""""institutional will"""""""" and are culturally empowered to execute our plan. Thus, Mayo is ready to implement the CTSA program aggressively and rapidly;the Mayo Clinic CCTR will be a highly functional and successful """"""""flagship"""""""" site for the CTSA program as it emerges from the NIH Roadmap. To summarize, the Mayo Clinic Center for Clinical and Translational Research (CCTR) will bring together all the resources of the five schools within the Mayo Clinic College of Medicine, and more than 100 years of scientific and medical research expertise, to discover innovative new methods that will speed the translation of research results into therapies, tools and patient care practices that impact all members of our local and national communities. This vision is entirely consistent with the stated mission of the Mayo Clinic to provide the best care to every patient every day.through integrated clinical practice, education and research.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1RR024150-04
Application #
7961437
Study Section
Special Emphasis Panel (ZRR1-CR-A (01))
Project Start
2009-07-01
Project End
2010-06-30
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
4
Fiscal Year
2009
Total Cost
$105,582
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chung, Jin Ook; Koutsari, Christina; Blachnio-Zablieska, Agnieszka Urszula et al. (2018) Effects of meal ingestion on intramyocellular ceramide concentrations and fractional de novo synthesis in humans. Am J Physiol Endocrinol Metab 314:E105-E114
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Cintron, Dahima; Lahr, Brian D; Bailey, Kent R et al. (2018) Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause 25:145-153
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Latreille, Veronique; St Louis, Erik K; Pavlova, Milena (2018) Co-morbid sleep disorders and epilepsy: A narrative review and case examples. Epilepsy Res 145:185-197
Shah, Saumya M; Martinez-Thompson, Jennifer M; Diehl, Nancy N et al. (2018) Adult-onset nonparalytic, small-angle hypertropia. J AAPOS 22:438-440
Jondal, Danielle E; Thompson, Scott M; Butters, Kim A et al. (2018) Heat Stress and Hepatic Laser Thermal Ablation Induce Hepatocellular Carcinoma Growth: Role of PI3K/mTOR/AKT Signaling. Radiology 288:730-738
Rhee, Rennie L; Davis, John C; Ding, Linna et al. (2018) The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol 13:251-257
Lu, Jin; Allred, Carolyn C; Jensen, Michael D (2018) Human adipose tissue protein analyses using capillary western blot technology. Nutr Diabetes 8:26
Dakhoul, Lara; Ghabril, Marwan; Gu, Jiezhun et al. (2018) Heavy Consumption of Alcohol is Not Associated With Worse Outcomes in Patients With Idiosyncratic Drug-induced Liver Injury Compared to Non-Drinkers. Clin Gastroenterol Hepatol 16:722-729.e2

Showing the most recent 10 out of 1084 publications